Invention:
This technology relates to a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin. This modified version of SHU9119 can antagonize the Melanocortin 5 Receptor (MC5R), potentially enabling rapidly-acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood disorders.
Background:
Current treatments for depression include drugs with delayed therapeutic onset. This technology has the potential to fill this unmet need with a therapy that is specific to MC5R for treating depression and other mood disorders.
Applications:
- Pharmaceutical compound for the treatment of depression, anxiety, and other mood disorders
Advantages:
- Targets specific receptor minimizes undesirable side effects
- May achieve therapeutic effect in less time than alternative pharmacological interventions
Status: issued U.S. patent #9,814,755
